This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
7 Apr 2013

Roche Launches New Metabolite Tests for its Cedex Bio Systems Offering the Most Comprehensive Testing Portfolio for Bioprocess Analytics

Roche has announced the launch of new metabolite-testing reagent sets to determine the concentration of iron and phosphate, two parameters relevant for cell growth and productivity during fermentation processes. The tests are designed for applications in research and bio-manufacturing process development and will allow the measurement of iron (complexed iron /Fe3+ ions) and phosphate on Cedex Bio instruments.

“The new tests ideally expand our metabolite testing portfolio for mammalian cell fermentation analytics. It is currently the most comprehensive portfolio combining iron and phosphate testing with other relevant parameters such as IgG, LDH and other standard metabolites,” said Ruedi Stoffel, Head of Biochemical Reagents and Custom Biotech. “Thanks to their reliability, precision, and ease of use, our Cedex instruments and the new testing portfolio are perfectly designed to optimize process development and monitoring of bio-pharmaceutical production particularly when using chemically defined media. The rapidly increasing customer base of our Cedex instruments will benefit from our continuously expanding testing portfolio.”

The new tests can be easily installed by barcode reading through the customer supporting the flexible testing concept. Offered as liquid-stable formulation, they are ready for use and do not require manual dilution or pipetting steps. With their increased precision, accuracy and long calibration intervals, the new iron and phosphate tests offer cost-effective and convenient testing with less hands-on time for users. 

Related News

  • News Federal judge blocks Colorado's unprecedented price cap on Amgen's Enbrel

    A US federal court has halted Colorado's attempt to impose a US$31,200 annual price cap on Amgen's arthritis drug Enbrel, ruling that the pharmaceutical company would likely suffer irreparable harm. The decision represents a significant blow to...
  • News Protecting life-saving therapies: CPHI Online Podcast Series

    The latest episode of the CPHI Podcast Series dives into a critical challenge facing the pharmaceutical industry: ensuring the integrity of temperature-sensitive medications and biologics through advanced predictive technology.

  • News 2026 Outsourcing Outlook Update - pharma at a crossroads

    The pharmaceutical contract development and manufacturing organisation (CDMO) sector is experiencing unprecedented transformation, driven by evolving therapeutic complexities, geopolitical tensions, and the growing demand for specialised manufacturing ...
  • News Roche maintains German investment commitment whilst rivals scale back

    Pharmaceutical giant Roche has reaffirmed its commitment to investing in Germany, standing firm even as competitors Eli Lilly and Boehringer Ingelheim dramatically reduce their planned investments in response to controversial healthcare reforms.

  • News Women in Pharma: The History of CPHI Women in Japan

    Our monthly Women in Pharma series highlights the influential lives and work of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive.
  • News EU drafts deal to end essential medicines shortage

    European negotiators have agreed new legislation to tackle persistent shortages of essential medicines by prioritising supply security over price in public procurement and supporting domestic pharmaceutical manufacturing with strategic funding.

  • News Thermo Fisher Scientific offloads microbiology business to PE firm Astorg

    The life sciences giant is divesting its global microbiology unit, which generated $645 million in revenue last year, to the pan-European private equity firm as part of an active portfolio management strategy. The transaction is expected to close in th...
  • News The Shift: Why Sustainability is Moving to the Centre of CPHI Milan 2026

    CPHI Online contributor David Roach takes a look at how conversations around sustainability in the pharmaceutical industry can and must be transformed into actionable deliveries, and what the inaugural CPHI Sustainability Summit means for the industry.